Calcium Channel blockers are associated with reduced risk of Parkinson's disease in patients with hypertension: A population-based retrospective cohort study

Association of orthostatic hypotension with Parkinson’s disease: a meta-analysis

(2020) Feifei Mu et al.   NEUROLOGICAL SCIENCES

The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease

(2019) Birgit Liss et al.   Annual Review of Pharmacology and Toxicology

Clinical Trial Highlights: Phase III Study in Spotlight

(2019) Kevin McFarthing et al.   Journal of Parkinsons Disease

Hypertension and Diagnosis of Parkinson’s Disease: A Meta-Analysis of Cohort Studies

(2018) Liyan Hou et al.   Frontiers in Neurology

Selective neuronal vulnerability in Parkinson disease

(2017) D. James Surmeier et al.   NATURE REVIEWS NEUROSCIENCE

Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease

(2017) Lena F. Burbulla et al.   SCIENCE

The epidemiology of Parkinson's disease: risk factors and prevention

(2016) Alberto Ascherio et al.   LANCET NEUROLOGY

Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice

(2016) Alpana Singh et al.   NEUROCHEMISTRY INTERNATIONAL

Use of Calcium Channel Blockers and Parkinson’s Disease

(2012) Björn Pasternak et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Calcium, Bioenergetics, and Neuronal Vulnerability in Parkinson's Disease

(2012) D. James Surmeier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease

(2012) Joshua A Goldberg et al.   NATURE NEUROSCIENCE

Association of Blood Pressure and Hypertension With the Risk of Parkinson Disease

(2011) Chengxuan Qiu et al.   HYPERTENSION

Drug-induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France

(2011) Emmanuelle Bondon-Guitton et al.   MOVEMENT DISORDERS

The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease

(2011) D.J. Surmeier et al.   NEUROSCIENCE

Oxidative Stress and Energy Crises in Neuronal Dysfunction

(2010) David G. Nicholls   Annals of the New York Academy of Sciences

Calcium channel blocker use and risk of Parkinson's disease

(2010) Kelly Claire Simon et al.   MOVEMENT DISORDERS

Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1

(2010) Jaime N. Guzman et al.   NATURE

Antihypertensive Agents and Risk of Parkinson’s Disease, Essential Tremor and Dementia: A Population-Based Prospective Study (NEDICES)

(2009) Elan D. Louis et al.   NEUROEPIDEMIOLOGY

Drug induced parkinsonism: a common cause of parkinsonism in older people

(2009) B Thanvi et al.   POSTGRADUATE MEDICAL JOURNAL

Basic Research on Dopamine in Parkinson’s Disease and the Discovery of the Nigrostriatal Dopamine Pathway: The View of an Eyewitness

(2008) Oleh Hornykiewicz   Neurodegenerative Diseases

Use of antihypertensives and the risk of Parkinson disease

(2008) C. Becker et al.   NEUROLOGY